Home › Melanoma › Pennsylvania
Melanoma clinical trials in Pennsylvania
47 studies for Melanoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069DESTINY-PANTUMOUR04
- Research Site, Philadelphia
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Thomas Jefferson University Hospital, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- St. Luke's University Health Network, Easton
- Penn State Health Milton South Hershey Medical Center, Hershey
- Fox Chase Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06246916Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT05727904A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 24, 2026 · NCT07621614Pan-tumor MRD Study
- Lancaster General Hospital (UPenn), Lancaster
- Guthrie Foundation, Sayre
- Cancer Care Associates of York (CCAY), York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Christiana Care Health System-Concord Health Center, Chadds Ford
- Fox Chase Cancer Center - East Norriton Hospital Outpatient Center, East Norriton
- UPMC Hillman Cancer Center Erie, Erie
- and 4 more
RecruitingPhase 3
Ages 75 and older · All sexes · Updated Sep 24, 2026 · NCT07068074BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT07070232Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05896839Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- and 4 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07115043Investigating Real-Time Immunotherapy Symptoms Study
- UPMC Hillman Cancer Center, Pittsburgh
Recruiting
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07280715Tebentafusp-tebn With LDT in Metastatic UM
- Thomas Jefferson University, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06626516Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06060613Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT04114136A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 11, 2026 · NCT05361174Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT04658303Evaluation of Hypoxia in Primary Melanoma
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT06831071MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Fox Chase Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Jun 10, 2026 · NCT05655312Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
- Fox Chase Cancer Center, Philadelphia
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT05498792ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Jefferson Health Honickman Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT06413680A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- UPenn, Philadelphia
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06624644A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT07223424RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06216938A Study of VET3-TGI in Patients With Solid Tumors
- UPMC- Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 7, 2026 · NCT06444815A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Thomas Jefferson University, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- WellSpan Medical Oncology and Hematology, Chambersburg
- and 13 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Thomas Jefferson University Medical Oncology Clinic, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT05549297Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
- St. Luke's University Health Network, Easton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT04903119Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 26, 2026 · NCT06599619Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Penn State Cancer Institute, Hershey
- Fox Chase Cancer Center 333 Cottman Avenue, Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT03567889From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.